Endpoints News
Crystalys moves quickly into Series B Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
22 July, 2026
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
presented by Viiv Healthcare
HIV Ends Here: In­side Vi­iV Health­care’s Sin­gu­lar Mis­sion
spotlight
bioregnum
top stories
1. Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
2. Crystalys gets $130M to take Sobi-rivaling gout drug to market
3. Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
4.
news briefing
Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
5. Updated: Summit reports two-year survival data for Western patients, though context lacking
6. Vertex was only bidder for Crinetics in year's second-highest M&A premium
7. Celldex scraps antibody in itchy skin nodules after Phase 2 flop
8. Trump pledges new tariffs on generic drugs not made in the US
9. Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
10. FDA plans to name permanent CBER, CDER heads with new commissioner nomination
more stories
• 
Karen Weintraub
.

Carole Ho, Lilly’s president of neuroscience, talks about why her company is getting back into neuropsych, decades after its creation of Prozac. In this Q&A with Ryan Cross, Ho also discusses the potential she sees for preventing Alzheimer’s.
.
Karen Weintraub
Deputy Editor, Endpoints News
Carole Ho, president of Lilly Neuroscience
1
by Ryan Cross

LON­DON — Eli Lil­ly, the world’s biggest drug­mak­er, ap­pears to be get­ting more am­bi­tious about tack­ling brain dis­eases.

Last week, the com­pa­ny an­nounced it would...

Read the full story
James Mackay, Crystalys Therapeutics CEO
2
by Kyle LaHucik

A San Diego biotech has raised an ad­di­tion­al $130 mil­lion to get a gout drug that's al­ready ap­proved in Japan and Chi­na on­to the US...

Read the full story
3
by Elizabeth Cairns

Ar­row­head Phar­ma­ceu­ti­cals’ lipid-low­er­ing drug has hit in two late-stage tri­als that could ex­pand its use in­to a much wider pop­u­la­tion.

Da­ta shared Wednes­dayshowed that...

Read the full story
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
News Briefing: Quick hits from the biopharma web
4
by Kyle LaHucik

An­oth­er $200M for Men­tari: Mi­graine drug de­vel­op­er Men­tari Ther&